

## **ENROLLMENT FORM**

Fax to: 844.295.5518

W// 101 0 1 11=10100 10			
DATE:	SHIP TO:		
DATE NEEDED:	☐ PATIENT ☐ OFFICE		

PHARMACY LOCATION 11233 SHADOW CREEK PARKWAY, SUITE 123A PEARLAND, TEXAS 77584 1.844.295.5516

NOTIFIED   PLEASE FAX COPY OF INSURANCE CARD (FRONT & BACK)   Public of diagnosis:	L									
Olagnosis:   Olate of diagnosis:   October:   Other:   October:   Other:   Olagnosis:   Olagnosis:   Olagnosis:   Olagnosis:   October:   Other:   Olagnosis:   Olagnosis:   Olagnosis:   October:   Other:   Olagnosis:   Olagnosi:   O	PA1	Address: Home Telephone:		Мо	City, State, Zip: SS#:					
Diagnosis:		-				CE CARD (FRONT & BA	CK)			
M06.9 Rheumatoid Arthritis   M81.0 Postmenop Osteo.   M97.0 Patient weight:   Dischause   Positive   Not applicable   M97.0 Postmenop Osteo.   M		• Diagnosis:				1	-	: □ Other:		
Drug   Dosage form/strength   Directions   Quantity   Refills	NO	MOS O PL								
Drug   Dosage form/strength   Directions   Quantity   Refills	ATI						oplicable			
Drug   Dosage form/strength   Directions   Quantity   Refills	RM			•						
Drug   Dosage form/strength   Directions   Quantity   Refills	FO									
Drug   Dosage form/strength   Directions   Quantity   Refills	<u></u>									
Drug   Dosage form/strength   Directions   Quantity   Refills	IICA	Prior Failed N	Medication(s)		Length of Tr	eatment	Reason for	r Discontinuing		
Drug   Dosage form/strength   Directions   Quantity   Refills	LIN .				to					
Drug   Dosage form/strength   Directions   Quantity   Refill:   RHEUMATOLOGY						-				
Cimzia®		Drug	Dosage form/st	ength		Direction	s	Quantity	Refills	
Cimzia@   Maintenance Dose:   Inject 400mg SC every 4 weeks   2 prefilled syr Other:		RHEUMATO	LOGY							
Prefilled Syringe (200mg/ml)   Inject 200mg SC every atther week   Other:					<u>Maintenance</u>	Directions:				
Cytoxan		Cimzia® <u>Maintenance Dose:</u>		_	- '	•				
Orencia   1 gram vial   2 gram vial   Administermg/kg via IV infusion every   vials				ı/ml)	☐ Inject 200mg	SC every <u>other</u> week		Other:		
IV only: Infusemg IV at weeks 0, 2, and 4, and every   wials   weeks thereafter   wials   walnistermg/kg everyweeks   wials   walnistermg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   wials   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter   walnister 2 mg/kg via IV inf at weeks 0& 4, then Q				2 gram vial	☐ Administer	mg/kg via IV infusion	every	□ vials		
Reclast   Other:	NO	Сусторноѕрпатисе		2 grain viai		71/	2 14 1		_	
Reclast   Other:	ИАТІ	Orencia <sup>®</sup>	☐ Vial (250mg/15ml)					□ vials		
Reclast   Other:	ORI	Remicade Uial (100mg/20ml)			Administer/mg/kg at 0,2 & wks, then q wks after			U vials		
Reclast   Other:	NFC						□ — vials			
Reclast   Other:	Z	Simponi Aria <sup>®</sup> □ 50mg/4ml vial		☐ Administer 2 mg/kg via IV inf at weeks 0& 4, then Q8 wks therafter			□ vials			
Reclast   Other:					☐ Other:					
Reclast   Other:	<u>~</u>	OSTEOPOROSIS								
OTHER MEDICATIONS								☐ 1 syringe		
Practitioner's Name: Telephone: Office Address: NPI#: DEA#:  DEA#:  DEA#:  Medicaid Provider #:			□ Vial (5mg/100ml)					☐ 1 syringe		
Practitioner's Name: Telephone: Office Address: NPI#: DEA#:  DEA#:  Contact person: Fax: City: State: Medicaid Provider #:		OTHER MEDICATIONS								
Practitioner's Name: Telephone:  Office Address: NPI#:  DEA#:  Contact person: Fax: City: State:  Medicaid Provider #:										
Telephone: Fax:  Office Address: City: State: Zip:  NPI#: DEA#: Medicaid Provider #:										
Telephone: Fax:  Office Address: City: State: Zip:  NPI#: DEA#: Medicaid Provider #:		Practitioner'	s Name:			Contact pers	on:			
	RIBER									
			s:		_			Zip:		
	ESC	NPI#:	[	EA#:		Medicaid Pr	ovider #:			
I authorize ReCept Pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization process.	PRI	PRODUCT SUBSTITUTION PERMITTED (DATE) DISPENSE AS WRITTEN (DATE)					=)			